Tiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results